Search Results
Your search for 3 matches 15284 pages
Showing 2151 - 2200AEGEAN Trial Shows Benefit With Immunotherapy-Based Combination for NSCLC
Patients with treatment-naive resectable non–small cell lung cancer (NSCLC) treated with neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response rates compared with those who received neoadjuvant chemotherapy...
Immunotherapy/Chemotherapy Combination Prolongs Survival in Advanced Biliary Tract Cancers
The addition of the checkpoint inhibitor pembrolizumab to chemotherapy with cisplatin/gemcitabine as first-line therapy improved overall survival in patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 trial presented at the 2023 American Association for Cancer...
Sotorasib in Pretreated Patients With KRAS G12C–Mutated NSCLC: 2-Year Analysis of CodeBreaK100
In an analysis published in the Journal of Clinical Oncology, Grace K. Dy, MD, and colleagues report 2-year outcomes of the CodeBreaK100 phase I/II trial of sotorasib in previously treated patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer (NSCLC). According...
Elena Garralda, MD, MSc, Discusses Findings From the KRYSTAL-1 Trial
Elena Garralda, MD, MSc, Director of Early Drug Development at Vall d’Hebron University Hospital and Director of the Phase I Unit at NEXT Oncology, Barcelona, was invited to discuss the KRYSTAL-1 findings. “In KRYSTAL-1, adagrasib monotherapy has demonstrated clinically meaningful activity in a...
KRYSTAL-1 Update: Adagrasib Yields Benefit in Variety of KRAS G12C–Mutated Tumors
In the phase I/II KRYSTAL-1 trial, the KRAS inhibitor adagrasib demonstrated clinical activity in previously treated patients with pancreatic ductal adenocarcinoma, biliary tract cancer, and other solid tumors harboring KRAS G12C mutations, according to research presented at the ASCO Plenary Series ...
First-in-Patient Study of PSMA-Targeted Fluorescent Tracer for Intraoperative Imaging of PSMA-Positive Prostate Cancer
In a single-institution Dutch phase IIa feasibility trial reported in The Lancet Oncology, Stibbe et al evaluated the pharmacokinetics and safety of the prostate-specific membrane antigen (PSMA)-targeted fluorescent tracer OTL78 in patients undergoing robot-assisted radical prostatectomy for...
Limited Surgery Plus Proton Therapy in Pediatric and Adolescent Patients With Craniopharyngioma
In a phase II trial (RT2CR) reported in The Lancet Oncology, Thomas E. Merchant, DO, and colleagues found that limited surgery plus proton therapy was associated with a high rate of disease control and a low rate of severe complications in pediatric and adolescent patients with craniopharyngioma....
Newly Identified Risk Factors May Point to a Heightened Risk for Early-Onset Colorectal Cancer Among Younger Adult Patients
Researchers have identified four warning signs and symptoms that may indicate an elevated risk of early-onset colorectal cancer, according to a new study published by Fritz et al in the Journal of the National Cancer Institute. The findings may be key to helping physicians more effectively detect...
Judy C. Boughey, MD, on Changes in Axillary Surgical Management: An I-SPY2 Analysis
Judy C. Boughey, MD, of the Mayo Clinic, discusses the decrease, over the past decade, of axillary lymph node dissection, especially in patients with node-positive breast cancer at diagnosis who had sentinel lymph node surgery after neoadjuvant chemotherapy. These findings are based on the records...
Addition of Tislelizumab to Chemotherapy in First-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
As reported in The Lancet Oncology by Xu et al, an interim analysis of the phase III RATIONALE-306 trial has shown improved overall survival with the addition of the anti–PD-1 antibody tislelizumab to chemotherapy in the first-line treatment of advanced or metastatic esophageal squamous cell...
pCR and Individual Patient Prognosis After Neoadjuvant Chemotherapy and Anti-HER2 Therapy in HER2-Positive Early Breast Cancer
In an analysis reported in the Journal of Clinical Oncology, Marion T. van Mackelenbergh, MD, PhD, and colleagues found that patients with early HER2-positive breast cancer who achieved pathologic complete response (pCR) on neoadjuvant chemotherapy plus anti-HER2 treatment had better overall and...
Addition of Blinatumomab to Chemotherapy in Infant Patients With KMT2A-Rearranged ALL
In a phase II trial reported in The New England Journal of Medicine, van der Sluis et al found that the addition of blinatumomab—a bispecific T-cell engager molecule targeting CD19—to standard chemotherapy appeared to result in marked improvements in outcome among infants with KMT2A-rearranged...
Survival in Patients With Neuroblastoma on Reduced Therapy as a Result of Change in COG Risk Stratification
In an analysis reported in the Journal of Clinical Oncology, Bender et al found that “excellent” survival outcomes were achieved in patients receiving reduced treatment for neuroblastoma as a result of reassignment to intermediate risk from high risk based on a change in the minimum age for...
First-Line Zolbetuximab Plus mFOLFOX6 in CLDN18.2-Positive, HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
As reported in The Lancet by Kohei Shitara, MD, and colleagues, the phase III SPOTLIGHT trial has shown significantly prolonged progression-free and overall survival with the addition of the anti–claudin-18 isoform 2 (CLDN18.2) antibody zolbetuximab to mFOLFOX6 (modified leucovorin [or...
Updated Analysis of Study 309/KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Previously Treated Patients With Advanced Endometrial Cancer
As reported in the Journal of Clinical Oncology by Vicky Makker, MD, and colleagues, an updated analysis of the phase III Study 309/KEYNOTE-775 trial showed overall and progression-free survival benefits with lenvatinib/pembrolizumab vs physician’s choice of chemotherapy among previously treated...
Addition of Quizartinib to Chemotherapy in Newly Diagnosed FLT3-ITD–Positive Acute Myeloid Leukemia
As reported in The Lancet by Erba et al, the phase III QuANTUM-First trial has shown prolonged overall survival with the addition of the FLT3 inhibitor quizartinib to chemotherapy in patients with newly diagnosed FLT3-internal-tandem-duplication (ITD)-positive acute myeloid leukemia (AML). Study...
Subcutaneous vs Intravenous Rituximab in First-Line Treatment of Low–Tumor Burden Follicular Lymphoma
In a French phase III trial (FLIRT) reported in the Journal of Clinical Oncology, Cartron et al found that the use of subcutaneous (SC) vs intravenous (IV) rituximab was associated with improved progression-free survival in the first-line treatment of low–tumor burden follicular lymphoma. Study...
Adjuvant Chemotherapy After Standard Chemoradiotherapy in Locally Advanced Cervical Cancer
As reported in The Lancet Oncology by Mileshkin et al, the phase III OUTBACK trial has shown no survival benefit with adjuvant carboplatin/paclitaxel chemotherapy given after standard cisplatin-based chemoradiotherapy as primary treatment in patients with locally advanced cervical cancer. Study...
In BRCA-Mutated Ovarian Cancer, Neoadjuvant Olaparib Feasible, Appears Effective in Pilot Study
Encouraging outcomes were achieved in patients with BRCA-mutated ovarian cancer who received neoadjuvant treatment with olaparib in a feasibility study led by Shannon N. Westin, MD, MPH, Professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD...
ASTRO and ESTRO Issue New Clinical Guidelines on Local Therapy for Patients With Oligometastatic NSCLC
The American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy & Oncology (ESTRO) provided advice on the use of definitive local therapy—including radiation and surgery—to treat patients with oligometastatic non–small cell lung cancer (NSCLC), according to new...
Trastuzumab Deruxtecan vs Physician’s Choice in HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine
As reported in The Lancet by André et al, the phase III DESTINY-Breast02 trial has shown improved progression-free survival with fam-trastuzumab deruxtecan-nxki vs physician’s choice of treatment in patients with HER2-positive metastatic breast cancer who had received prior ado-trastuzumab...
KRYSTAL-1 Update: Adagrasib Yields Benefit in Variety of KRAS G12C–Mutated Tumors
In the phase I/II KRYSTAL-1 trial, the KRAS inhibitor adagrasib demonstrated promising clinical activity in previously treated patients with pancreatic ductal adenocarcinoma, biliary tract cancer, and other solid tumors harboring KRAS G12C mutations, according to research presented at the April...
Third-Line Treatment of Follicular Lymphoma
This is Part 3 of Advances in Follicular Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Stephen M. Ansell, Loretta J. Nastoupil, and Gilles Salles discuss the third-line treatment of follicular lymphoma. The patient...
Homage to a Giant in Hematology: The Fascinating Story of the Quest to Cure Leukemia
Bone marrow transplantation in leukemia is one of the great success stories in the history of oncology, as is that of the late Nobel Laureate E. Donnall Thomas, MD, the pioneering clinical researcher whose name is synonymous with life-saving marrow transplantation. Dr. Thomas, who was born in the...
Dabrafenib With Trametinib for Pediatric Low-Grade Glioma With BRAF V600E Mutation
On March 16, 2023, dabrafenib with trametinib was approved for pediatric patients aged 1 year and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.1,2 The U.S. Food and Drug Administration also approved new oral formulations of both drugs suitable for patients who ...
I’m BRCA-Positive and Survived Both Breast and Pancreatic Cancers
Cancer has stalked my family for generations. My mother, brother, and maternal uncle were diagnosed with melanoma. Fortunately, all survived. When my sister was diagnosed with early-stage invasive ductal carcinoma in 2010, she underwent genetic testing, which showed she was positive for the BRCA2...
Emerging Success With Novel Targeted Therapies in Endocrine-Resistant Metastatic Breast Cancer
In hormone receptor–positive breast cancer, the ability to successfully target key mediators of endocrine resistance is changing the outlook of metastatic disease in this subtype, according to Aditya Bardia, MD, MPH, FASCO, Director of Breast Cancer Research and Associate Professor at Harvard...
Using Circulating Tumor DNA to Predict Early Recurrence of Soft-Tissue Sarcomas
Circulating tumor DNA (ctDNA) may transform disease monitoring and guide treatment for soft-tissue sarcomas, according to data presented at the 2023 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care.1 Findings of a retrospective review showed that 85% of patients...
Social Drivers of Health: Grabbing the Steering Wheel
Study after study has demonstrated race-based differences in survival and other clinical outcomes for patients with cancer. But as health professionals, we are learning that these differences are less about a patient’s skin color and more about the legacy of racial inequality.1 This knowledge...
Expert Point of View: Yelena Y. Janjigian, MD
The GLOW study’s invited discussant, Yelena Y. Janjigian, MD, Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, New York, said the GLOW findings are “practice-changing,” validating that high claudin-18.2 (CLDN18.2) expression as an important biomarker in...
GLOW Trial: Zolbetuximab Plus Chemotherapy Sets New Treatment Standard in Gastric Cancer Subset
In the first-line setting, the monoclonal antibody zolbetuximab in combination with chemotherapy extended overall survival in patients with claudin-18.2 (CLDN18.2)-positive, HER2-negative, locally advanced or metastatic gastric adenocarcinoma. This regimen is now positioned as a new standard of...
Expert Point of View: Rebecca Arend, MD, MSH and Ilaria Colombo, MD
“Endometrial cancer is the most frequently diagnosed gynecologic malignancy in the United States, and it is the only one where the mortality has actually risen over the past 40 years,” noted Rebecca Arend, MD, MSH, Associate Professor at the University of Alabama and Associate Scientist in the...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Extreme Poverty May Be a Key Driver for Relapse in Pediatric Patients With ALL
Pediatric patients with acute lymphoblastic leukemia (ALL) living in extreme poverty and undergoing maintenance therapy may have almost a twofold greater risk of relapse compared with pediatric patients who weren’t living in extreme poverty, according to a new study published by Wadhwa et al in...
Neoadjuvant Trabectedin and Radiotherapy in Myxoid Liposarcoma
In the phase II TRASTS study reported in JAMA Oncology, Sanfilippo et al found that neoadjuvant trabectedin and radiotherapy did not meet the target objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) in patients with myxoid liposarcoma but did exhibit activity...
Toripalimab Plus Chemotherapy May Improve Event-Free Survival in Resectable Stage III NSCLC
An interim analysis of the Neotorch study highlighted the potential of immunotherapy for the treatment of early-stage non–small cell lung cancer (NSCLC), according to data presented by Lu et al during the ASCO Plenary Series: April 2023 Session (Abstract 425126). The findings showed a significant...
Locally Advanced High-Risk Prostate Cancer
This is Part 3 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss the management of locally advanced high-risk...
Early Trial Results Show Potential Benefits of FGFR Inhibitors and PARP/ATR Inhibitor Combinations in Multiple Tumor Types
In three new clinical trials, researchers have found that the novel fibroblast growth factor receptor (FGFR) inhibitor pemigatinib and new poly (ADP ribose) polymerase (PARP)/ataxia telangiectasia and Rad3-related (ATR) inhibitor combinations may be effective at treating patients with multiple...
COVID-19 Pandemic May Have Disrupted Cancer Reporting in 2020 and Beyond
Investigators have uncovered factors contributing to the COVID-19 pandemic’s destabilization of the usual patterns of cancer care, described specific ways that National Cancer Database data models were impacted by the pandemic, and offered guidance to cancer centers across the United States on how...
Association of Delayed or Foregone Care Among Patients With Cancer and Patient-Clinician Identity Discordance
In a study reported in a research letter in JAMA Oncology, Patel et al found that delayed or foregone care due to patient-clinician discordance of identity (eg, race, religion, gender) was more common among patients with cancer vs noncancer controls. Approximately one-quarter of younger patients...
Sugemalimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma
In a Chinese phase II study (GEMSTONE-201) reported in the Journal of Clinical Oncology, Huang et al found that the PD-L1 inhibitor sugemalimab produced durable responses in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma. Study Details In the multicenter trial, 78...
Study Identifies Mutations That May Be Associated With Poor Outcomes in Patients With NSCLC Treated With KRAS G12C Inhibitors
Researchers have discovered that co-occurring mutations in three tumor-suppressor genes—KEAP1, SMARCA4, and CDKN2A—may be linked with poor clinical outcomes in patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) who were treated with the KRAS G12C inhibitors adagrasib or sotorasib,...
VT3989 May Be Safe, Effective in Patients With Advanced Mesothelioma and NF2-Mutant Solid Tumors
The yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD) inhibitor VT3989 may have been well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma as well as other NF2-mutated solid tumors, according to new findings presented by Yap et...
FDA Approves Polatuzumab Vedotin-piiq Plus R-CHP for Previously Untreated DLBCL–Not Otherwise Specified and High-Grade B-Cell Lymphoma
On April 19, the U.S. Food and Drug Administration (FDA) approved the antibody-drug conjugate polatuzumab vedotin-piiq (Polivy) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for previously untreated adult patients who have diffuse large B-cell lymphoma (DLBCL)–not...
Investigational Deep Learning Model May Help Stratify Risk of Distant Recurrence in Patients With Endometrial Cancer
An investigational deep learning model requiring one histopathologic slide may be effective at predicting the risk of distant recurrence in patients with endometrial cancer, according to novel findings presented by Fremond et al at the American Association for Cancer Research (AACR) Annual Meeting...
Psilocybin Therapy for Patients With Cancer and Major Depression Disorder
In a phase II study reported in a research letter in JAMA Oncology, Agrawal et al found that a single treatment with psilocybin (COMP360) with a 1:1 therapist-to-patient ratio reduced symptoms of depression in patients with cancer and major depression disorder treated at a single community cancer...
Bispecific Antibody REGN5459 Shows Activity in Patients With Relapsed or Refractory Multiple Myeloma
Although the 5-year relative survival rate for multiple myeloma is improving—up from 34.6% in 1998 to 53.9% in 2016—due to the approval of more effective therapies, multiple myeloma remains incurable, and new treatment options are needed, especially in the relapsed/refractory setting. A small phase ...
FDA Approves Omidubicel-onlv to Reduce Time to Neutrophil Recovery and Infection in Patients With Hematologic Malignancies
On April 17, the U.S. Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge) for use in adult and pediatric patients aged 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time ...
IMbrave050: Recurrence-Free Survival With Adjuvant Atezolizumab Plus Bevacizumab for HCC
Adjuvant therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to results from the phase III IMbrave050 clinical trial, which were presented by Chow et al at the American...
Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma
Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by Kendra et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract...
